Translating Human Effective Jejunal Intestinal Permeability to Surface-Dependent Intrinsic Permeability: a Pragmatic Method for a More Mechanistic Prediction of Regional Oral Drug Absorption

AAPS Journal

Volumn 17, Issue 5, 2015, Pages 1177-1192

  Olivares Morales, Andrés ^a   Lennernäs, Hans ^b   Aarons, Leon ^a   Rostami Hodjegan, Amin ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UPPSALA UNIVERSITY   (Sweden)

^c CERTARA UK LIMITED   (United Kingdom)

Author keywords

intestinal permeability; oral drug absorption; physiologically based pharmacokinetic modelling

Indexed keywords

ATENOLOL; CIMETIDINE; ENALAPRILAT; FLUINDOSTATIN; FUROSEMIDE; GRISEOFULVIN; HYDROCHLOROTHIAZIDE; HYDROCORTISONE; KETOPROFEN; METOPROLOL; NAPROXEN; PARACETAMOL; PHENAZONE; PROPRANOLOL; RANITIDINE; SALICYLIC ACID; TALINOLOL; TERBUTALINE; TRIAMCINOLONE ACETONIDE; DRUG;

ARTICLE; ASCENDING COLON; COLON ABSORPTION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG RELEASE; GASTROINTESTINAL TRACT; HUMAN; HUMAN TISSUE; ILEUM; INTESTINE MUCOSA PERMEABILITY; JEJUNUM; PREDICTION; SMALL INTESTINE ABSORPTION; TRANSVERSE COLON; BIOLOGICAL MODEL; INTESTINE ABSORPTION; METABOLISM; ORAL DRUG ADMINISTRATION; PERMEABILITY;

ADMINISTRATION, ORAL; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL ABSORPTION; JEJUNUM; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS;

EID: 84939564502     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-015-9758-0     Document Type: Article

References (86)

1. Sinko PJ, Leesman GD, Amidon GL. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm Res. 1991;8(8):979–88. doi:10.1023/A:1015892621261.
2. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20.
3. Lennernas H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica. 2007;37(10–11):1015–51. doi:10.1080/00498250701704819.
4. Lennernas H. Human in vivo regional intestinal permeability: importance for pharmaceutical drug development. Mol Pharm. 2014;11(1):12–23. doi:10.1021/mp4003392.
5. Lennernas H. Regional intestinal drug permeation: biopharmaceutics and drug development. Eur J Pharm Sci. 2014;57:333–41. doi:10.1016/j.ejps.2013.08.025.
6. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev. 2001;50(Suppl 1(0)):S41–67. doi:10.1016/S0169-409X(01)00179-X.
7. Thelen K, Coboeken K, Willmann S, Burghaus R, Dressman JB, Lippert J. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. J Pharm Sci. 2011;100(12):5324–45. doi:10.1002/jps.22726.
8. Willmann S, Schmitt W, Keldenich J, Lippert J, Dressman JB. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem. 2004;47(16):4022–31. doi:10.1021/jm030999b.
9. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol. 2009;5(2):211–23. doi:10.1517/17425250802691074.
10. Sjogren E, Westergren J, Grant I, Hanisch G, Lindfors L, Lennernas H, et al. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Eur J Pharm Sci. 2013;49(4):679–98. doi:10.1016/j.ejps.2013.05.019.
11. Gertz M, Houston JB, Galetin A. Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab Dispos. 2011;39(9):1633–42. doi:10.1124/dmd.111.039248.
12. Lennernas H. Human intestinal permeability. J Pharm Sci. 1998;87(4):403–10. doi:10.1021/js970332a.
13. Lennernas H, Ahrenstedt O, Hallgren R, Knutson L, Ryde M, Paalzow LK. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm Res. 1992;9(10):1243–51. doi:10.1023/A:1015888813741.
14. Knutson L, Odlind B, Hallgren R. A new technique for segmental jejunal perfusion in man. Am J Gastroenterol. 1989;84(10):1278–84.
15. Knutson T, Fridblom P, Ahlstrom H, Magnusson A, Tannergren C, Lennernas H. Increased understanding of intestinal drug permeability determined by the LOC-I-GUT approach using multislice computed tomography. Mol Pharm. 2009;6(1):2–10. doi:10.1021/mp800145r.
16. Lennernas H, Lee ID, Fagerholm U, Amidon GL. A residence-time distribution analysis of the hydrodynamics within the intestine in man during a regional single-pass perfusion with Loc-I-Gut: in-vivo permeability estimation. J Pharm Pharmacol. 1997;49(7):682–6. doi:10.1111/j.2042-7158.1997.tb06092.x.
17. Sugano K, Kansy M, Artursson P, Avdeef A, Bendels S, Di L, et al. Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov. 2010;9(8):597–614. doi:10.1038/nrd3187.
18. Amidon GL, Kou J, Elliott RL, Lightfoot EN. Analysis of models for determining intestinal wall permeabilities. J Pharm Sci. 1980;69(12):1369–73.
19. Fagerholm U, Lennernäs H. Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug absorption. Eur J Pharm Sci. 1995;3(5):247–53. doi:10.1016/0928-0987(95)00027-B.
20. Dahan A, Miller JM, Hilfinger JM, Yamashita S, Yu LX, Lennernas H, et al. High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. Mol Pharm. 2010;7(5):1827–34. doi:10.1021/mp100175a.
21. Dahan A, Lennernas H, Amidon GL. The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Mol Pharm. 2012;9(6):1847–51. doi:10.1021/mp300140h.
22. Watts PJ, Illum L. Colonic drug delivery. Drug Dev Ind Pharm. 1997;23(9):893–913. doi:10.3109/03639049709148695.
23. International Commission on Radiological Protection. Report of the Task Group on Reference Man: Pergamon Press; 1975.
24. Coupe AJ, Davis SS, Evans DF, Wilding IR. Nocturnal scintigraphic imaging to investigate the gastrointestinal transit of dosage forms. J Control Release. 1992;20(2):155–62. doi:10.1016/0168-3659(92)90161-J.
25. Tannergren C, Bergendal A, Lennernas H, Abrahamsson B. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. Mol Pharm. 2009;6(1):60–73. doi:10.1021/mp800261a.
26. Thelen K, Coboeken K, Willmann S, Dressman JB, Lippert J. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: extension to describe performance of solid dosage forms. J Pharm Sci. 2012;101(3):1267–80. doi:10.1002/jps.22825.
27. Willmann S, Edginton AN, Kleine-Besten M, Jantratid E, Thelen K, Dressman JB. Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption. J Pharm Pharmacol. 2009;61(7):891–9. doi:10.1211/jpp/61.07.0008.
28. Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009;11(2):225–37. doi:10.1208/s12248-009-9099-y.
29. Woltosz WS, Bolger MB, Lukacova V. Modeling of absorption. Methods Mol Biol. 2012;929:313–36. doi:10.1007/978-1-62703-050-2_13.
30. Carlert S, Lennernas H, Abrahamsson B. Evaluation of the use of Classical Nucleation Theory for predicting intestinal crystalline precipitation of two weakly basic BSC class II drugs. Eur J Pharm Sci. 2014;53:17–27. doi:10.1016/j.ejps.2013.12.004.
31. Yu LX, Lipka E, Crison JR, Amidon GL. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev. 1996;19(3):359–76. doi:10.1016/0169-409X(96)00009-9.
32. Yu LX, Crison JR, Amidon GL. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm. 1996;140(1):111–8. doi:10.1016/0378-5173(96)04592-9.
33. Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm. 1999;186(2):119–25. doi:10.1016/S0378-5173(99)00147-7.
34. Kesisoglou F, Wu Y. Understanding the effect of API properties on bioavailability through absorption modeling. AAPS J. 2008;10(4):516–25. doi:10.1208/s12248-008-9061-4.
35. Rubinstein A. Colonic drug delivery. Drug Discov Today Technol. 2005;2(1):33–7. doi:10.1016/j.ddtec.2005.05.021.
36. Wilson JP. Surface area of the small intestine in man. Gut. 1967;8(6):618–21.
37. DeSesso JM, Jacobson CF. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol. 2001;39(3):209–28. doi:10.1016/S0278-6915(00)00136-8.
38. Wilson TH. Intestinal absorption. Philadelphia: W.B. Saunders Company; 1962.
39. Helander HF, Fändriks L. Surface area of the digestive tract—revisited. Scand J Gastroenterol. 2014;49(6):681–9. doi:10.3109/00365521.2014.898326.
40. Valentin J. Basic anatomical and physiological data for use in radiological protection: reference values. Ann ICRP. 2002;32(3–4):1–277. doi:10.1016/s0146-6453(03)00002-2.
41. Hounnou G, Destrieux C, Desme J, Bertrand P, Velut S. Anatomical study of the length of the human intestine. Surg Radiol Anat. 2002;24(5):290–4. doi:10.1007/s00276-002-0057-y.
42. Sadahiro S, Ohmura T, Yamada Y, Saito T, Taki Y. Analysis of length and surface-area of each segment of the large-intestine according to age, sex and physique. Surg Radiol Anat. 1992;14(3):251–7. doi:10.1007/Bf01794949.
43. Sinclair TS, Jones DA, Kumar PJ, Phillips AD. The microvillus in adult jejunal mucosa—an electron microscopic study. Histopathology. 1984;8(5):739–46.
44. Gramatte T, Oertel R, Terhaag B, Kirch W. Direct demonstration of small intestinal secretion and site-dependent absorption of the [beta]-blocker talinolol in humans [ast]. Clin Pharmacol Ther. 1996;59(5):541–9.
45. Gramatte T, Richter K. Paracetamol absorption from different sites in the human small intestine. Br J Clin Pharmacol. 1994;37(6):608–11.
46. Gramatte T, el Desoky E, Klotz U. Site-dependent small intestinal absorption of ranitidine. Eur J Clin Pharmacol. 1994;46(3):253–9. doi:10.1007/BF00192558.
47. Gramatte T. Griseofulvin absorption from different sites in the human small intestine. Biopharm Drug Dispos. 1994;15(9):747–59. doi:10.1002/bdd.2510150903.
48. Sutcliffe FA, Riley SA, Kaserliard B, Turnberg LA, Rowland M. Absorption of drugs from the human jejunum and ileum. Br J Clin Pharmacol. 1988;26(2):P206–7.
49. Schedl HP. Absorption of steroid hormones from the human small intestine. J Clin Endocrinol Metab. 1965;25(10):1309–16. doi:10.1210/jcem-25-10-1309.
50. Amidon GL, Sinko PJ, Fleisher D. Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res. 1988;5(10):651–4. doi:10.1023/a:1015927004752.
51. Musther H, Olivares-Morales A, Hatley OJ, Liu B, Rostami Hodjegan A. Animal versus human oral drug bioavailability: do they correlate? Eur J Pharm Sci. 2014;57:280–91. doi:10.1016/j.ejps.2013.08.018.
52. McBride G. A proposal for strength-of-agreement criteria for Lin’s concordance correlation coefficient. NIWA Client Report: HAM2005-062. 2005.
53. Yu LX, Amidon GL. Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur J Pharm Biopharm. 1998;45(2):199–203. doi:10.1016/S0939-6411(97)00088-X.
54. Read NW, Al-Janabi MN, Holgate AM, Barber DC, Edwards CA. Simultaneous measurement of gastric emptying, small bowel residence and colonic filling of a solid meal by the use of the gamma camera. Gut. 1986;27(3):300–8.
55. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small-intestine. Gut. 1986;27(8):886–92. doi:10.1136/Gut.27.8.886.
56. Yu LX, Amidon GL. Characterization of small intestinal transit time distribution in humans. Int J Pharm. 1998;171(2):157–63. doi:10.1016/S0378-5173(98)00174-4.
57. Bouchoucha M, Devroede G, Dorval E, Faye A, Arhan P, Arsac M. Different segmental transit times in patients with irritable bowel syndrome and “normal” colonic transit time: is there a correlation with symptoms? Tech Coloproctol. 2006;10(4):287–96. doi:10.1007/s10151-006-0295-9.
58. Bouchoucha M, Thomas SR. Error analysis of classic colonic transit time estimates. Am J Physiol Gastrointest Liver Physiol. 2000;279(3):G520–7.
59. Sugano K. Estimation of effective intestinal membrane permeability considering bile micelle solubilisation. Int J Pharm. 2009;368(1–2):116–22. doi:10.1016/j.ijpharm.2008.10.001.
60. Lennernas H. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J Pharm Pharmacol. 1997;49(7):627–38. doi:10.1111/j.2042-7158.1997.tb06084.x.
61. Fagerholm U, Johansson M, Lennernas H. Comparison between permeability coefficients in rat and human jejunum. Pharm Res. 1996;13(9):1336–42. doi:10.1023/A:1016065715308.
62. Brasitus TA, Dudeja PK. Regional differences in the lipid composition and fluidity of rat colonic brush-border membranes. Biochim Biophys Acta. 1985;819(1):10–7. doi:10.1016/0005-2736(85)90189-0.
63. Brasitus TA, Dudeja PK. Alterations in the physical state and composition of brush border membrane lipids of rat enterocytes during differentiation. Arch Biochem Biophys. 1985;240(1):483–8. doi:10.1016/0003-9861(85)90054-2.
64. Brasitus TA, Dudeja PK, Bolt MJ, Sitrin MD, Baum C. Dietary triacylglycerol modulates sodium-dependent D-glucose transport, fluidity and fatty acid composition of rat small intestinal brush-border membrane. Biochim Biophys Acta. 1989;979(2):177–86. doi:10.1016/0005-2736(89)90433-1.
65. Dahlgren D, Roos C, Sjogren E, Lennernas H. Direct in vivo human intestinal permeability (Peff) determined with different clinical perfusion and intubation methods. J Pharm Sci. 2014. doi:10.1002/jps.24258.
66. Sjoberg A, Lutz M, Tannergren C, Wingolf C, Borde A, Ungell AL. Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique. Eur J Pharm Sci. 2013;48(1–2):166–80. doi:10.1016/j.ejps.2012.10.007.
67. Ungell AL, Nylander S, Bergstrand S, Sjoberg A, Lennernas H. Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci. 1998;87(3):360–6. doi:10.1021/js970218s.
68. Johnson TN, Zhou D, Bui KH. Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents. Biopharm Drug Dispos. 2014;35(6):341–52. doi:10.1002/bdd.1899.
69. Watson KJ, Davis J, Jones HM. Application of physiologically based pharmacokinetic modeling to understanding the clinical pharmacokinetics of UK-369,003. Drug Metab Dispos. 2011;39(7):1203–13. doi:10.1124/dmd.111.038224.
70. Parrott N, Lukacova V, Fraczkiewicz G, Bolger MB. Predicting pharmacokinetics of drugs using physiologically based modeling–application to food effects. AAPS J. 2009;11(1):45–53. doi:10.1208/s12248-008-9079-7.
71. Lukacova V, Woltosz WS, Bolger MB. Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data. AAPS J. 2009;11(2):323–34. doi:10.1208/s12248-009-9107-2.
72. Patel N, Polak S, Jamei M, Rostami-Hodjegan A, Turner DB. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine. Eur J Pharm Sci. 2014;57:240–9. doi:10.1016/j.ejps.2013.09.006.
73. Olivares-Morales A, Kamiyama Y, Darwich AS, Aarons L, Rostami-Hodjegan A. Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model. Eur J Pharm Sci. 2015;67:32–44. doi:10.1016/j.ejps.2014.10.018.
74. Lennernäs H, Nylander S, Ungell AL. Jejunal permeability: a comparison between the Ussing chamber technique and the single-pass perfusion in humans. Pharm Res. 1997;14(5):667–71. doi:10.1023/a:1012121632357.
75. Lennernas H. Animal data: the contributions of the Ussing chamber and perfusion systems to predicting human oral drug delivery in vivo. Adv Drug Deliv Rev. 2007;59(11):1103–20. doi:10.1016/j.addr.2007.06.016.
76. Lennernas H, Aarons L, Augustijns P, Beato S, Bolger M, Box K, et al. Oral biopharmaceutics tools—time for a new initiative—an introduction to the IMI project OrBiTo. Eur J Pharm Sci. 2014;57:292–9. doi:10.1016/j.ejps.2013.10.012.
77. Stenberg P, Luthman K, Artursson P. Virtual screening of intestinal drug permeability. J Control Release. 2000;65(1–2):231–43. doi:10.1016/S0168-3659(99)00239-4.
78. Gertz M, Harrison A, Houston JB, Galetin A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos. 2010;38(7):1147–58. doi:10.1124/dmd.110.032649.
79. Akamatsu M, Fujikawa M, Nakao K, Shimizu R. In silico prediction of human oral absorption based on QSAR analyses of PAMPA permeability. Chem Biodivers. 2009;6(11):1845–66. doi:10.1002/cbdv.200900112.
80. Tavelin S, Taipalensuu J, Soderberg L, Morrison R, Chong SH, Artursson P. Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers. Pharm Res. 2003;20(3):397–405. doi:10.1023/A:1022699920043.
81. Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennernas H, Karlen A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem. 1998;41(25):4939–49. doi:10.1021/jm9810102.
82. Sun D, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, et al. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res. 2002;19(10):1400–16. doi:10.1023/A:1020483911355.
83. Schiller C, Frohlich CP, Giessmann T, Siegmund W, Monnikes H, Hosten N, et al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2005;22(10):971–9. doi:10.1111/j.1365-2036.2005.02683.x.
84. Sutton SC. Role of physiological intestinal water in oral absorption. AAPS J. 2009;11(2):277–85. doi:10.1208/s12248-009-9087-2.
85. Fallingborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, Rasmussen HH. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther. 1989;3(6):605–13. doi:10.1111/j.1365-2036.1989.tb00254.x.
86. Granero GE, Longhi MR, Mora MJ, Junginger HE, Midha KK, Shah VP, et al. Biowaiver monographs for immediate release solid oral dosage forms: furosemide. J Pharm Sci. 2010;99(6):2544–56. doi:10.1002/jps.22030.